ArticlePloS one2015
Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis.Medicine · 2019Pooled it
- Switching from Cation-Exchange Resin to Sodium Zirconium Cyclosilicate Hydrate in Patients on Hemodialysis.Journal of clinical medicine · 2026Article
- Klotho's Impact on Cardiovascular Disease, Fractures, and Mortality in Hemodialysis.Kidney international reports · 2025Article
- Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease.Frontiers in medicine · 2025Article
- Lower serum magnesium levels are associated with a higher risk of fractures and vascular calcifications in hemodialysis patients.Clinical kidney journal · 2025Article
- Monitoring of serum magnesium levels during long-term use of proton pump inhibitors in elderly japanese patients: is it really necessary or not?Journal of pharmaceutical health care and sciences · 2022Article
- Magnesium exposure increases hip fracture risks in patients with chronic kidney disease: a population-based nested case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.Osteoarthritis and cartilage · 2022Article
- Fibroblast growth factor 23 is independently associated with renal magnesium handling in patients with chronic kidney disease.Frontiers in endocrinology · 2022Article
- Higher Soluble ACE2 Levels and Increased Risk of Infection-Related Hospitalization in Patients on Maintenance Hemodialysis.Frontiers in medicine · 2022Article
- Use of proton pump inhibitors in dialysis patients: a double-edged sword?Journal of nephrology · 2021Review
- Article
- Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients.Human cell · 2020Article
- A questionnaire on prescription patterns of proton pump inhibitors for hemodialysis patients in Japan.Clinical and experimental nephrology · 2020Article
- Observational
- Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2018Article
- Ionized and total serum magnesium in hemodialysis: predictors and variability. A longitudinal cross-sectional study.Clinical and experimental nephrology · 2018Article
- Magnesium and Risk of Hip Fracture among Patients Undergoing Hemodialysis.Journal of the American Society of Nephrology : JASN · 2018Article
- Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.PloS one · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnesium concentration is a proven predictor of mortality in hemodialysis patients. Recent reports have indicated that proton pump inhibitor (PPI) use affects serum magnesium levels, however few studies have investigated the relationship between PPI use and magnesium levels in hemodialysis patients. This study aimed to clarify the association between PPI use and serum magnesium levels in hemodialysis patients. We designed this cross sectional study and included 1189 hemodialysis patients in stable condition. Associations between PPI and magnesium-related factors, as well as other possible confounders, were evaluated using a multiple regression model. We defined hypomagnesemia as a value < 2.0 mg/dL, and created comparable logistic regression models to assess the association between PPI use and hypomagnesemia. PPI use is associated with a significantly lower mean serum magnesium level than histamine 2 (H2) receptor antagonists or no acid-suppressive medications (mean [SD] PPI: 2.52 [0.45] mg/dL; H2 receptor antagonist: 2.68 [0.41] mg/dL; no acid suppressive medications: 2.68 [0.46] mg/dL; P = 0.001). Hypomagnesemia remained significantly associated with PPI (adjusted OR, OR: 2.05; 95% CI: 1.14-3.69; P = 0.017). PPI use is associated with an increased risk of hypomagnesemia in hemodialysis patients. Future prospective studies are needed to explore magnesium replacement in PPI users on hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.